Evidence map›Paper›PMID 40200016›Full record

ArticleScientific reports2025

Novel serum biomarker associations with 7 Tesla MRI-defined cortical lesions, leptomeningeal enhancement, and deep gray matter volume in early multiple sclerosis.

Andrei Miclea, Jonathan Zurawski, Brian C Healy, Shrishti Saxena, Hrishikesh Lokhande, Molly Quattrucci, Renxin Chu, Howard L Weiner, Rohit Bakshi, Tanuja Chitnis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrei Miclea *Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Jonathan Zurawski *Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Brian C HealyBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Shrishti SaxenaBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Hrishikesh LokhandeBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Molly QuattrucciBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Renxin ChuBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Howard L WeinerBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Rohit BakshiBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Tanuja ChitnisBrigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA. tchitnis@bwh.harvard.edu.

Funding

U.S. Department of Defense (United States Department of Defense) W81XWH1810648
6 · The paper itself

Abstract

Gray matter demyelinating lesions, brain atrophy and meningeal inflammation are hypothesized to be relevant in multiple sclerosis (MS) disease pathogenesis, though their relationship to immune alterations in early MS is not well characterized. This study aims to investigate correlations between the concentrations of 112 serum proteins and 7 Tesla MRI-defined measures of disease severity in patients with early MS. In this analysis, patients with CIS or MS having a 7 Tesla brain MRI and blood sample both within five years of MS diagnosis were included (n = 57). Correlational analysis was adjusted for sex, age, and disease duration. Correlation between serum proteins and MRI-defined cortical and thalamic gray matter lesions, leptomeningeal enhancement (presence and foci number), deep gray matter (DGM) structure volumes, whole brain parenchymal volume and total T2 white matter lesion volume was assessed. In this study, cortical lesions were associated with higher IL-15, TNF-alpha, and BAFF levels, and lower levels of FcRL2. Leptomeningeal enhancement was associated with higher levels of PLXNB3 and lower levels of nCDase and CNTN5. Higher IL-1B levels correlated with lower DGM volume while higher levels of CDH6, SIGLEC9, and HAGH correlated with higher DGM volume. These novel associations between serum immune proteins and 7 T MRI outcomes may have relevance as disease biomarkers in early stages of MS.

Indexed as

BiomarkersGray MatterMagnetic Resonance ImagingMeningesMultiple SclerosisAdultFemaleHumansMaleMiddle AgedBiomarkers7 TeslaBiomarkersCortical lesionsDeep gray matter lesionsLeptomeningeal enhancementMultiple sclerosis

Identifiers

PMID40200016
PMCPMC11978968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.